Clinical trials: Healthy Male Volunteers
Healthy
Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers
The primary objective of this study is to characterize the metabolic disposition, pharmacokinetics (PK), and routes of elimination of [14C]-labeled BVD-523 after administration of a single, oral dose to healthy male subjects.
- Trial name
- NCT02994732
- Testing
- [14C]-BVD-523
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- BioMed Valley Discoveries, Inc
Healthy
Effect of Food on the Pharmacokinetics of AQW051 in Japanese Healthy Male Subjects
This study will evaluate safety, tolerability and pharmacokinetics of individual oral doses of AQW051 in Japanese healthy male subjects, and will also evaluate the effect of food on the pharmacokinetics of AQW051.
- Trial name
- NCT00409500
- Testing
- AQW051
- Where
- Japan
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Novartis
Healthy
BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone.
This study is to evaluate the safety/tolerability and pharmacokinetics of the combinations of gemigliptin 50mg and metformin HCl extended release 1000mg in comparison to each component administered in healthy male volunteers.
- Trial name
- NCT02056600
- Testing
- gemigliptin and metformin HCl extended release, gemigliptin/metformin HCl sustained release
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Healthy
Safety and Pharmacokinetic Characteristics of HD203 in Healthy Male Volunteers
The purpose of this study is compare the safety and pharmacokinetic characteristics of HD203 with those of etanercept after subcutaneous injection in healthy male volunteers.
- Trial name
- SPH (NCT01044836)
- Testing
- HD203
- Where
- South Korea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hanwha Chemical
Healthy Volunteers
First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants
This is a Phase 1, first-in-human study involving single and multiple oral doses of TS-161 in healthy male and female participants. The safety, tolerability, pharmacokinetics and pharmacodynamics of TS-161 will be evaluated.
- Trial name
- NCT03919409
- Testing
- TS-161
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Taisho Pharmaceutical R&D Inc.
Healthy Volunteers
Study to Evaluate a Pharmacokinetic of HM61713 in Healthy Male Subjects
Study Design Open, escalating single-dose design. 7 ascending dose cohorts In each cohorts, subjects will receive a single dose of HM61713. Main objective of this study is to evaluate the pharmacokinetics of HM61713 tablet.
- Trial name
- NCT01894399
- Testing
- HM61713
- Where
- South Korea
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy
PK, Safety & Tolerability of CyCol® Versus Sandimmune® in Healthy Subjects
The aim of this Phase I, single centre, multi stage study is to evaluate the safety, tolerability, pharmacokinetics and relative colonic mucosal concentrations of cyclosporine capsules (CyCol®) compared to intravenous…
- Trial name
- CYC102 (NCT02130414)
- Testing
- Sandimmun® IV, CyCol® capsules
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sigmoid Pharma
Renal Impairment, Healthy Volunteers
A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People
This study is for adults whose kidneys do not work well (renal impairment) and adults whose kidneys work normally. This study will provide more information on a potential new treatment, called ASP0367.
- Trial name
- NCT05117294
- Testing
- Bocidelpar
- Where
- 4 sites in United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Essential Hypertension
A Study to Evaluate the Effect of Fimasartan on Pharmacokinetics, and the Safety of Digoxin in Healthy Male Volunteers
The purpose of this study is to evaluate the effect of fimasartan on pharmacokinetics, and the safety of digoxin.
- Trial name
- NCT00991783
- Testing
- Digoxin + Fimasartan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension and Chronic Heart Failure
Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.
The purpose of this study is to to assess the safety and tolerability of BIA 5 1058 after single and multiple oral doses
- Trial name
- NCT02151994
- Testing
- BIA 5-1058
- Where
- Netherlands
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Autosomal Dominant Polycystic Kidney
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers
The study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Oral AL01211 in healthy volunteers
- Trial name
- NCT04908462
- Where
- Australia
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- AceLink Therapeutics, Inc.
Type 2 Diabetes
Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)
This study is designed to investigate the food-effects on FDC(gemigliptin/metformin HCl sustained release) 50/1000mg(25/500mg x 2tablets)
- Trial name
- NCT01747083
- Testing
- FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Healthy
Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers
The purpose of this study is to determine whether treatment with a fixed dose combination dapagliflozin/metformin tablet is affected by food.
- Trial name
- NCT01156246
- Testing
- Dapagliflozin/Metformin
- Where
- Sweden
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers
Randomized, double blind, parallel group, single dose, 3 arm study to investigate and compare the Pharmacokinetics (PK), safety and immunogenicity profile of MB02 with US and EU Avastin® in healthy male subjects.
- Trial name
- NCT03293654
- Testing
- MB02, US licenced Avastin®, EU approved Avastin®
- Where
- 2 sites in United Kingdom
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- mAbxience Research S.L.
Healthy
Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects
The purpose of the study is to determine how quickly AZD5122 is absorbed into and cleared by the body when given to healthy, non smoking males at different dose levels.
- Trial name
- NCT00984477
- Testing
- AZD5122
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Relative Bioavailability
To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers
This is a single-center, randomized, open, single-dose, three-cycle cross-design study, which will be only enrolled Chinese male healthy volunteers.
- Trial name
- CRC-C1721 (NCT03483259)
- Testing
- Sulfatinib T capsule, Sulfatinib R capsule
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hutchison Medipharma Limited
Pomalidomide Bioequivalence Study in Healthy Volunteers
Bioequivalence Study Comparing Two Pomalidomide 4 mg Capsule Formulations in Healthy Male Subjects
This study evaluated the bioequivalence and tolerability of a test pomalidomide formulation (Xetrane® 4 mg hard capsule) compared with the reference formulation (Imnovid® 4 mg hard capsule) in healthy male subjects under fasting…
- Trial name
- PRO-BEQ-PMD-00 (NCT07694011)
- Testing
- Xetrane® (Pomalidomide) 4 mg Hard Capsule, Imnovid® (Pomalidomide) 4 mg Hard Capsule
- Where
- Chile
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Knight Therapeutics (USA) Inc
Healthy
Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.
The objective of the current study is to investigate safety, tolerability, and pharmacokinetics of treatment with BI 661051 rising single doses administered as oral drinking solution (powder in bottle) in healthy male subjects.
- Trial name
- NCT01343719
- Testing
- BI 661051
- Where
- Germany
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Bioavailability of BI 1356 and Glyburide in Healthy Male and Female Volunteers
The objective of this study was to investigate the effect of multiple doses BI 1356 given once daily in the estimated highest therapeutic dose of 5 mg until steady state on the pharmacokinetics, safety, and tolerability of a…
- Trial name
- NCT02183428
- Testing
- BI 1356, Glyburide, BI 1356 + Glyburide
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Male Volunteers
First-time-in-man, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP1.5375
Phase I Single Ascending Dose (Part 1), phase IIa Proof Of Concept (Part 2)
- Trial name
- NCT01965301
- Testing
- BP1.5375 suspension, Diphenhydramine
- Where
- Netherlands
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bioprojet
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.